Sembragiline misses AD endpoint

Evotec AG (Xetra:EVT) said sembragiline ( RG1577; EVT 302) missed the primary endpoint in a Phase IIb trial to treat moderately severe Alzheimer's disease. In the MAyflOwer RoAD study conducted by Evotec partner Roche (SIX:ROG; OTCQX:RHHBY), sembragiline failed to significantly improve scores on a cognitive subscale of the Alzheimer's Disease Assessment Scale (ADAS-Cog11) after 52 weeks.

Roche spokesperson Stepan Kracala told BioCentury the company will analyze additional data from the trial, but declined to say when the company will decide next steps for sembragiline. ...